唐源電氣(300789.SZ):擬向唐源新材料增資
格隆匯7月22日丨唐源電氣(300789.SZ)公佈,基於控股子公司成都唐源新材料科技有限責任公司(簡稱“唐源新材料”)未來整體發展戰略考慮,爲了更好地推進業務發展,唐源新材料雙方股東經協商,擬按照每1元註冊資本對應1元人民幣的價格,以貨幣方式對唐源新材料進行增資。增資後唐源新材料註冊資本將由200萬元增加至1500萬元,共增資1300萬元,其中唐源電氣認購933萬元註冊資本,成都聚之賢企業管理中心(有限合夥)(以下簡稱“聚之賢”)認購367萬元註冊資本,本次增資完成後,唐源新材料仍屬於公司合併報表範圍內的控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.